Inventor · disambiguated record
Friederike Gieseke
Also filed as: GIESEKE FRIEDERIKE
16 granted patents·15 pending applications·44 citations·filing 2016–2025
91Inventor score
Top patents by PatentIndex Score
31 records- 0198US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0298US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0396US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 0495US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 0595US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 0687US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
- 0787US10669322B2RNA molecules encoding cytokine fusion proteins and methods of use thereofBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Jun 2, 2020·4 cites·28 claims
- 0886US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 0982US10968280B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2020·Granted Apr 6, 2021·1 cites·12 claims
- 1082US2023089969A1Multispecific antibodies against cd40 and cd137GENMAB AS·Filed 2022·Application pending·0 cites
- 1179US10301368B2Cytokine fusion proteinsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted May 28, 2019·4 cites·22 claims
- 1277US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 1374US11814411B2Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)BioNTech SE·Filed 2021·Granted Nov 14, 2023·0 cites·14 claims
- 1473US2024173382A1Therapeutic RNASANOFI SA·Filed 2023·Application pending·0 cites
- 1573US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1672US10927181B2Agonistic tumor necrosis factor (TNF) receptor binding agentsBioNTech SE·Filed 2019·Granted Feb 23, 2021·0 cites·20 claims
- 1772US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1871US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1971US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2067US11865159B2Therapeutic RNASANOFI SA·Filed 2021·Granted Jan 9, 2024·0 cites·30 claims
- 2165US2020147176A1Therapeutic RNASANOFI SA·Filed 2019·Application pending·0 cites
- 2259US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 2357US11932693B2Monoclonal antibodies directed against programmed death-1 protein and their use in medicineBioNTech SE·Filed 2023·Granted Mar 19, 2024·0 cites·30 claims
- 2456US10457735B2Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domainsBIONTECH AG·Filed 2016·Granted Oct 29, 2019·0 cites·3 claims
- 2555US2025002600A1Multispecific binding agents against pd-l1 and cd137 in combination therapyGENMAB AS·Filed 2022·Application pending·0 cites
- 2652US10808019B2Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligandsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2019·Granted Oct 20, 2020·0 cites·21 claims
- 2752US2024327544A1Multispecific binding agents against cd40 and cd137 in combination therapy for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 2850US2022040218A1Therapeutic RNA for Advanced Stage Solid Tumor CancersSANOFI SA·Filed 2021·Application pending·0 cites
- 2950US2021369842A1Antibody formulationGENMAB AS·Filed 2019·Application pending·0 cites
- 3050US2022288199A1Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor CancersSANOFI SA·Filed 2021·Application pending·0 cites
- 3148US2023399403A1Monoclonal antibodies directed against programmed death-1 protein and their use in medicineBioNTech SE·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Friederike Gieseke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →